Merck & Co., Inc. Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
Merck & Co., Inc. (MRK) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $28.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2026-02-24
- Merck & Co., Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2011-06-30 was $700.00M.
- Merck & Co., Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2025 was $28.00M, a 55.56% increase from fiscal 2024.
- Merck & Co., Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2024 was $18.00M, a 21.74% decline from fiscal 2023.
- Merck & Co., Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2023 was $23.00M, a 283.33% increase from fiscal 2022.
- Merck & Co., Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2022 was $6.00M, a 86.96% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 3 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 6 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month |
|---|---|---|---|
| 2025-12-31 | $28.00M 10-K · filed 2026-02-24 | ||
| 2024-12-31 | $18.00M 10-K · filed 2026-02-24 | ||
| 2023-12-31 | $23.00M 10-K · filed 2026-02-24 | ||
| 2022-12-31 | $6.00M 10-K · filed 2025-02-25 | ||
| 2021-12-31 | $46.00M 10-K · filed 2024-02-26 | ||
| 2020-12-31 | $70.00M 10-K · filed 2023-02-24 | ||
| 2019-12-31 | $356.00M 10-K · filed 2022-02-25 | ||
| 2018-12-31 | $91.00M 10-K · filed 2021-02-25 | ||
| 2017-12-31 | $1.39B 10-K · filed 2020-02-26 | ||
| 2016-12-31 | $92.00M 10-K · filed 2019-02-27 | ||
| 2015-12-31 | $184.00M 10-K · filed 2018-02-27 | ||
| 2014-12-31 | $161.00M 10-K · filed 2017-02-28 | ||
| 2013-12-31 | $603.00M 10-K · filed 2016-02-26 | ||
| 2012-12-31 | $67.00M 10-K · filed 2015-02-27 | ||
| 2011-12-31 | $259.00M 10-K · filed 2014-02-27 | ||
| 2011-06-30 | $700.00M 10-Q · filed 2011-11-08 | $700.00M 10-Q · filed 2011-08-08 | |
| 2010-12-31 | $256.00M 10-K · filed 2013-02-28 | ||
| 2009-12-31 | $332.00M 10-K · filed 2012-02-28 | ||
| 2008-12-31 | $39.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |